HomeNDC LookupRxCUI directory › RxCUI 901812

Velaglucerase alfa 400 UNT Injection [Vpriv] — RxCUI 901812

RxNorm drug concept · Semantic branded drug
RxCUI 901812 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI901812
Official nameVelaglucerase alfa 400 UNT Injection [Vpriv]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVpriv 400 UNT Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)463 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Velaglucerase alfa 400 UNT Injection [Vpriv] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Velaglucerase alfa 400 UNT Injection [Vpriv] RxCUI 901812

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Velaglucerase alfa 901805
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vpriv 901809
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Velaglucerase alfa Injection 1727288
    • Velaglucerase alfa Injectable Product 1164571
    • Velaglucerase alfa Injection [Vpriv] 1727291
    • Vpriv Injectable Product 1187597
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Velaglucerase alfa 400 UNT Injection SCD · 901808
  • Velaglucerase alfa 400 UNT SCDC · 1727287
  • Velaglucerase alfa Injection SCDF · 1727288
  • Velaglucerase alfa Injectable Product SCDG · 1164571

Brand-Name Concepts

  • Velaglucerase alfa 400 UNT [Vpriv] SBDC · 1727290
  • Velaglucerase alfa Injection [Vpriv] SBDF · 1727291
  • Vpriv Injectable Product SBDG · 1187597
  • Vpriv BN · 901809

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 901812 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
54092-0701-04 1 VIAL, GLASS in 1 BOX (54092-701-04) / 4 mL in 1 VIAL, GLA... VPRIV Takeda Pharmaceuticals America, Inc. 2010-02-26
Observed labelers: Takeda Pharmaceuticals America, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J3385 Velaglucerase alfa 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.